MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

Phase 1 Completed 32 enrolled Nivalis Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindBasic science

Summary

The present study is designed to assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects.

Timeline

Start: 2016-10
Primary completion: 2016-12
Completion: 2017-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cavosonstat	Small molecule	400 mg	Oral
Subject	Cavosonstat	Small molecule	600 mg	Oral
Subject	Cavosonstat	Small molecule	800 mg	Oral
Subject	Cavosonstat	Small molecule	1200 mg	Oral

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

Summary

Timeline

Drugs

Indications